Premaxillary Injection for Perioral Rejuvenation and Upper Lip Enhancement
| Registry | NCT03273543 |
|---|---|
| Status | Completed |
| Phase | Not applicable |
| Study type | Interventional; non randomized, parallel, masking: none, treatment |
| Enrollment | 20 (Actual) |
| Sponsor | DeNova Research (Other) |
| Conditions | Perioral Rejuvenation, Upper Lip Projection |
| Interventions | Restylane® Defyne (Device) |
| Dates | start 2017-11-20, primary completion 2018-07-03, completion 2018-07-03, first posted 2017-09-06, last updated 2020-10-08 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Perioral Rejuvenation All trials for Upper Lip Projection All trials of Restylane® Defyne
To determine if subjects who receive premaxillary injection demonstrate an increase in nasal tip projection and an associated increase in upper lip projection, and vermillion height.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Nasal Tip Projection | Experimental | Device: Restylane® Defyne | |
| Upper Lip Position | Experimental | Device: Restylane® Defyne |
Sex: All, ages: 21 Years to 70 Years, accepts healthy volunteers
Inclusion Criteria: * 1\. Subjects Age 21 to 70. 2. Subjects who demonstrate signs of perioral aging or poor upper lip projection. Exclusion Criteria: * 1\. Subjects who plan to undergo peri oral neurotoxin treatments or ablative skin treatments, or have had either of these treatments in the previous 6 months, other injectable filler treatments during the course of the study. 2\. Subjects who are pregnant or nursing. 3. Subjects with a known allergy or sensitivity to any component of the study ingredients. 4\. Any history of rhinoplasty or nasal filler injections. 5. Recent history of upper lip augmentation (surgical and non-surgical) within the last 12 months. 6\. Any history of lip lift or other surgical procedures involving the upper lip. 7\. Any history of chin augmentation (surgical and non-surgical). 8. Any history of orthognathic surgery. 9. Any history of bleeding disorders (iatrogenic or otherwise). 10. Current history of chronic drug or alcohol abuse. 11. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study product (i.e. immunosuppressive therapy). 12\. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non¬compliance with medical treatment or unreliability.
| Milestone | Nasal Tip Projection | Upper Lip Position |
|---|---|---|
| Started | 10 | 10 |
| Completed | 10 | 10 |
| Not completed | 0 | 0 |
Time frame: 2 months
| Arm | Deaths | Serious adverse events | Other adverse events |
|---|---|---|---|
| Nasal Tip Projection | 0/10 (0.0%) | 0/10 (0.0%) | 0/10 (0.0%) |
| Upper Lip Position | 0/10 (0.0%) | 0/10 (0.0%) | 0/10 (0.0%) |
| Facility | City | Country | Status |
|---|---|---|---|
| DeNova Research | Chicago, Illinois | United States |